Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIP-3α DNA vaccine
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins University
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
The MIP-3α DNA vaccine (also known as MipRel) is a research-stage therapeutic DNA vaccine developed by researchers at Johns Hopkins University. It consists of a DNA plasmid encoding a fusion protein of macrophage-inflammatory protein 3α (MIP-3α/CCL20) and the Mycobacterium tuberculosis antigen RelMtb. The vaccine is designed to target vaccine antigens specifically to immature dendritic cells (iDCs) via the interaction between the MIP-3α moiety and the CCR6 receptor. This targeting enhances dendritic cell activation and subsequent T-cell responses against M. tuberculosis. RelMtb is a (p)ppGpp synthase/hydrolase that plays a critical role in bacterial persistence and antibiotic tolerance. The vaccine is administered intranasally and has demonstrated synergy with the antitubercular drug isoniazid in preclinical models.
- Other names
- MIP-3α-antigen fusion DNA vaccineCCL20-RelMtb DNA vaccineCCL-20-RelMtb DNA vaccineCCL 20-RelMtb DNA vaccine
02
Targets
CCR6 (C-C motif chemokine receptor 6)
Beyond the preview
Go deeper on MIP-3α DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIP-3α DNA vaccine.